DK2172211T3 - Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers - Google Patents

Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers Download PDF

Info

Publication number
DK2172211T3
DK2172211T3 DK08017305T DK08017305T DK2172211T3 DK 2172211 T3 DK2172211 T3 DK 2172211T3 DK 08017305 T DK08017305 T DK 08017305T DK 08017305 T DK08017305 T DK 08017305T DK 2172211 T3 DK2172211 T3 DK 2172211T3
Authority
DK
Denmark
Prior art keywords
cancer
peptide
cell
peptides
tumor
Prior art date
Application number
DK08017305T
Other languages
Danish (da)
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Steffen Walter
Claudia Trautwein
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK2172211T3 publication Critical patent/DK2172211T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
DK08017305T 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers DK2172211T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Publications (1)

Publication Number Publication Date
DK2172211T3 true DK2172211T3 (en) 2015-02-16

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
DK08017305T DK2172211T3 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
DK08017921.1T DK2172212T3 (da) 2008-10-01 2008-10-13 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179214.8T DK3124043T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK09778749.3T DK2331118T5 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
DK16179174.4T DK3120868T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK09778750.1T DK2341927T3 (en) 2008-10-01 2009-09-28 Hitherto unknown immunotherapy for a variety of tumors, including neuronal and brain tumors
DK16165070.0T DK3069728T3 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
DK16179226.2T DK3120870T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179192.6T DK3120869T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179241.1T DK3111952T3 (en) 2008-10-01 2009-09-28 Hitherto unknown immunotherapy for a variety of tumors, including nerve and brain tumors

Family Applications After (11)

Application Number Title Priority Date Filing Date
DK08017921.1T DK2172212T3 (da) 2008-10-01 2008-10-13 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder neuronale tumorer og hjernetumorer
DK16179214.8T DK3124043T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK09778749.3T DK2331118T5 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
DK16179174.4T DK3120868T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179169.4T DK3132801T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK09778750.1T DK2341927T3 (en) 2008-10-01 2009-09-28 Hitherto unknown immunotherapy for a variety of tumors, including neuronal and brain tumors
DK16165070.0T DK3069728T3 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
DK16179226.2T DK3120870T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179192.6T DK3120869T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179163.7T DK3106175T3 (da) 2008-10-01 2009-09-28 Hidtil ukendt immunterapi mod flere forskellige tumorer, herunder nerve- og hjernetumorer
DK16179241.1T DK3111952T3 (en) 2008-10-01 2009-09-28 Hitherto unknown immunotherapy for a variety of tumors, including nerve and brain tumors

Country Status (24)

Country Link
US (19) US8318677B2 (enExample)
EP (12) EP2172211B1 (enExample)
JP (10) JP5855940B2 (enExample)
KR (6) KR102133402B1 (enExample)
CN (3) CN102170901B (enExample)
AU (2) AU2009300087B2 (enExample)
BR (2) BRPI0920759A2 (enExample)
CA (9) CA2739387C (enExample)
CY (11) CY1116302T1 (enExample)
DK (12) DK2172211T3 (enExample)
EA (3) EA023013B1 (enExample)
ES (12) ES2536465T3 (enExample)
HR (12) HRP20170115T1 (enExample)
HU (11) HUE031030T2 (enExample)
LT (10) LT2172212T (enExample)
MX (3) MX2011003539A (enExample)
NZ (4) NZ591882A (enExample)
PL (12) PL2172211T3 (enExample)
PT (12) PT2172211E (enExample)
RS (12) RS53782B1 (enExample)
SI (12) SI2172211T1 (enExample)
TR (2) TR201900809T4 (enExample)
UA (3) UA110599C2 (enExample)
WO (2) WO2010037513A1 (enExample)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012079878A2 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
RS54147B1 (sr) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
CA3066981A1 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
WO2013052158A2 (en) * 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
ES2856091T3 (es) 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CN104427984A (zh) * 2012-01-20 2015-03-18 D·布朗 包括二脱水半乳糖醇和类似物的经取代的己糖醇类于治疗包括多形性胶质母细胞瘤和成神经管细胞瘤的肿瘤疾病和癌症干细胞的用途
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
RS62406B1 (sr) * 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
CN109748953B (zh) * 2013-08-05 2022-09-02 伊玛提克斯生物技术有限公司 用于治疗多种肿瘤(例如包括nsclc在内的肺癌)的新型免疫疗法
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
RU2708311C2 (ru) 2014-04-25 2019-12-05 Блубёрд Био, Инк. Химерные антигенные рецепторы с mnd-промотором
DK3134095T3 (da) 2014-04-25 2020-06-29 Bluebird Bio Inc Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
EP3640262A1 (en) 2014-12-12 2020-04-22 Bluebird Bio, Inc. Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy
PT3626729T (pt) * 2014-12-23 2021-11-03 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso na imunoterapia contra o carcinoma hepatocelular (chc) e outros cancros
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
MY199500A (en) 2015-03-17 2023-11-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
CN107810193B (zh) * 2015-05-06 2022-03-22 伊玛提克斯生物技术有限公司 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US11305002B2 (en) 2015-06-09 2022-04-19 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for Haemophilus influenzae
ES2879248T3 (es) 2015-06-24 2021-11-22 Immodulon Therapeutics Ltd Inhibidor de puntos de control y micobacteria de célula completa para su uso en terapia contra el cáncer
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL256303B2 (en) * 2015-07-06 2025-02-01 Immatics Biotechnologies Gmbh New peptides and peptide combinations for use in immunotherapy against esophageal cancer and other cancers
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI803835B (zh) 2015-08-28 2023-06-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) * 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN109620949A (zh) * 2016-03-13 2019-04-16 曹帅 一种用于治疗骨癌的药物组合物
MY193474A (en) 2016-03-16 2022-10-15 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
KR20220097524A (ko) * 2016-04-06 2022-07-07 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
US11517598B2 (en) * 2016-10-03 2022-12-06 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses
AU2017355504C1 (en) 2016-11-04 2024-06-20 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US10174122B2 (en) 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
WO2018208856A1 (en) * 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2019118793A2 (en) * 2017-12-14 2019-06-20 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
HUE060791T2 (hu) * 2018-04-11 2023-04-28 Enterome S A Antigén peptidek rák megelõzésére és kezelésére
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CA3105381A1 (en) 2018-07-11 2020-01-16 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
WO2020201048A1 (en) 2019-03-29 2020-10-08 Intervet International B.V. Stabilisation of live mollicutes bacteria in a liquid composition
GB2599510B (en) * 2019-04-05 2023-08-30 Earli Inc Improved methods and compositions for synthetic biomarkers
CA3137880A1 (en) 2019-05-28 2020-12-03 Rodrigo CEBALLOS LENTINI Systems and methods for processing images to prepare slides for processed images for digital pathology
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
KR20220127847A (ko) * 2020-01-10 2022-09-20 더 브리검 앤드 우먼즈 하스피털, 인크. 뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물
AU2020431140A1 (en) * 2020-02-24 2022-08-18 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113444149A (zh) * 2020-03-18 2021-09-28 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
EP4305211A1 (en) * 2021-03-09 2024-01-17 BostonGene Corporation Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) * 2022-03-30 2025-07-24 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102907303B1 (ko) 2024-12-23 2025-12-31 전남대학교산학협력단 다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법
CN120272531B (zh) * 2025-06-10 2025-08-19 鼐济医药科技(杭州)有限公司 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0879282B1 (en) 1996-01-17 2003-07-02 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
WO1998003197A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
WO1998036062A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002529048A (ja) * 1997-12-02 2002-09-10 メダレツクス・インコーポレーテツド 抗−Ｆｃ受容体結合成分を発現する細胞
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
AU2001241406A1 (en) * 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020132753A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
AU2003298984A1 (en) * 2002-12-27 2004-08-23 Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US20060241166A1 (en) 2003-04-04 2006-10-26 Pharmacyclica, Inc. Sapphyrins and uses thereof
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
CA2554195C (en) * 2004-01-23 2011-02-22 Green Peptide Co., Ltd. Peptide originating in epidermal growth factor receptor (egfr)
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
ES2534752T3 (es) * 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
ES2330013T3 (es) * 2005-09-05 2009-12-03 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas.
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) * 2007-03-06 2008-09-12 Barry G. Arnason Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2009125394A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
KR102311038B1 (ko) * 2014-05-28 2021-10-07 노노 인코포레이티드 Tat-nr2b9c의 클로라이드 염
CA3021159A1 (en) * 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)

Also Published As

Publication number Publication date
PT3120868T (pt) 2020-07-16
CA2936868A1 (en) 2010-04-08
JP2017029135A (ja) 2017-02-09
PT3120870T (pt) 2020-07-01
US20160376316A1 (en) 2016-12-29
CY1122677T1 (el) 2021-03-12
US20160376313A1 (en) 2016-12-29
EP2331118B1 (en) 2016-10-26
EP3069728A1 (en) 2016-09-21
ES2536465T3 (es) 2015-05-25
US11136352B2 (en) 2021-10-05
DK3069728T3 (en) 2019-02-25
PL2172212T3 (pl) 2017-04-28
US8895514B2 (en) 2014-11-25
PL3106175T3 (pl) 2020-08-24
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
LT3106175T (lt) 2020-08-10
PT2172211E (pt) 2015-03-09
NZ591882A (en) 2012-12-21
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
US20100158931A1 (en) 2010-06-24
US9993540B2 (en) 2018-06-12
ES2802227T3 (es) 2021-01-18
HUE041446T2 (hu) 2019-05-28
JP5855940B2 (ja) 2016-02-09
JP2016047825A (ja) 2016-04-07
HRP20190202T1 (hr) 2019-03-22
EA201100586A1 (ru) 2011-10-31
HRP20201025T8 (hr) 2022-01-07
LT2172212T (lt) 2016-11-10
US20160376314A1 (en) 2016-12-29
KR20200085381A (ko) 2020-07-14
PT3069728T (pt) 2019-02-13
RS58229B1 (sr) 2019-03-29
KR102392070B1 (ko) 2022-04-29
HUE051030T2 (hu) 2021-01-28
DK3120868T3 (da) 2020-06-22
ES2819244T3 (es) 2021-04-15
EP3120870B1 (en) 2020-04-01
SI3120870T1 (sl) 2020-08-31
US12234298B2 (en) 2025-02-25
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
NZ591855A (en) 2012-11-30
CA2739384A1 (en) 2010-04-08
MX2011003539A (es) 2011-06-20
BRPI0920791A2 (pt) 2019-12-10
KR101883426B1 (ko) 2018-07-31
NZ603016A (en) 2014-05-30
DK3120870T3 (da) 2020-06-22
CA2936869C (en) 2019-08-06
ES2770090T3 (es) 2020-06-30
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
HUE047365T2 (hu) 2020-04-28
CN102170901B (zh) 2015-01-07
CA2739384C (en) 2017-05-02
HUE042115T2 (hu) 2019-06-28
US10906936B2 (en) 2021-02-02
LT3132801T (lt) 2020-02-10
KR20110082155A (ko) 2011-07-18
SI2172212T1 (sl) 2016-12-30
US20210347822A1 (en) 2021-11-11
EP3124043B1 (en) 2020-04-29
JP2014239681A (ja) 2014-12-25
TR201900809T4 (tr) 2019-02-21
HRP20150223T8 (hr) 2015-07-03
PL3120870T3 (pl) 2020-07-27
BRPI0920759A2 (pt) 2016-03-08
HK1161106A1 (en) 2012-08-24
JP2012504563A (ja) 2012-02-23
EP3132801A1 (en) 2017-02-22
US10919931B2 (en) 2021-02-16
JP2017018101A (ja) 2017-01-26
US20120141517A1 (en) 2012-06-07
KR101756488B1 (ko) 2017-07-11
CY1119744T1 (el) 2018-06-27
HRP20200722T1 (hr) 2020-10-16
EA032437B1 (ru) 2019-05-31
ES2584245T3 (es) 2016-09-26
DK2341927T3 (en) 2016-08-15
JP2012504393A (ja) 2012-02-23
US10046037B2 (en) 2018-08-14
HRP20201015T8 (hr) 2022-01-21
HRP20201015T1 (hr) 2020-10-16
WO2010037514A3 (en) 2010-06-03
US8653035B2 (en) 2014-02-18
DK3106175T3 (da) 2020-06-22
KR20160103558A (ko) 2016-09-01
PT3124043T (pt) 2020-05-12
EP2341927B1 (en) 2016-05-04
KR101687840B1 (ko) 2016-12-19
SI3069728T1 (sl) 2019-03-29
PL2172211T3 (pl) 2015-05-29
PT2331118T (pt) 2017-02-06
EP3124043A1 (en) 2017-02-01
PL3124043T3 (pl) 2020-07-27
CY1123113T1 (el) 2021-10-29
RS58443B1 (sr) 2019-04-30
CA2936924A1 (en) 2010-04-08
CA2936920C (en) 2019-12-03
KR20220058655A (ko) 2022-05-09
SI3120868T1 (sl) 2020-08-31
AU2009300088A1 (en) 2010-04-08
BRPI0920791B8 (pt) 2022-02-15
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
RS55543B1 (sr) 2017-05-31
KR102133402B1 (ko) 2020-07-14
HRP20201228T1 (hr) 2021-02-05
JP6150859B2 (ja) 2017-06-21
PL2341927T3 (pl) 2016-11-30
KR20180088494A (ko) 2018-08-03
CY1116302T1 (el) 2017-02-08
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
HRP20200110T1 (hr) 2020-05-15
PT3111952T (pt) 2019-02-05
CA2936924C (en) 2019-07-16
MX338294B (es) 2016-04-11
EP3120868A1 (en) 2017-01-25
SI3124043T1 (sl) 2020-07-31
HRP20150223T1 (hr) 2015-06-05
US20210253637A1 (en) 2021-08-19
AU2009300087A1 (en) 2010-04-08
ES2708654T3 (es) 2019-04-10
DK3120869T3 (da) 2020-08-10
DK3111952T3 (en) 2019-01-28
AU2009300087B2 (en) 2014-09-04
CN102170900A (zh) 2011-08-31
CA2936869A1 (en) 2010-04-08
US20130309193A1 (en) 2013-11-21
US20130004456A1 (en) 2013-01-03
RS53782B1 (sr) 2015-06-30
WO2010037513A1 (en) 2010-04-08
CN106986919A (zh) 2017-07-28
PT2172212T (pt) 2016-12-22
SI3111952T1 (sl) 2019-01-31
DK2172212T3 (da) 2016-12-19
EP2341927A2 (en) 2011-07-13
EP2172211A1 (en) 2010-04-07
CY1123098T1 (el) 2021-10-29
HRP20160915T1 (hr) 2016-10-07
PT3120869T (pt) 2020-09-22
CA2936920A1 (en) 2010-04-08
US10047123B2 (en) 2018-08-14
US12221493B2 (en) 2025-02-11
PT2341927T (pt) 2016-08-02
JP6294914B2 (ja) 2018-03-14
UA110599C2 (uk) 2016-01-25
SI2331118T1 (sl) 2017-01-31
SI3132801T1 (sl) 2020-03-31
DK3124043T3 (da) 2020-05-04
AU2009300088B2 (en) 2014-09-04
CY1123526T1 (el) 2022-03-24
JP6214066B2 (ja) 2017-10-18
PL3120868T3 (pl) 2020-08-24
US10047124B2 (en) 2018-08-14
TR201900852T4 (tr) 2019-02-21
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
CY1123089T1 (el) 2021-10-29
EP3111952B1 (en) 2018-10-31
EP3120870A1 (en) 2017-01-25
EP3120869A1 (en) 2017-01-25
HRP20161504T1 (hr) 2016-12-30
HRP20182151T1 (hr) 2019-02-08
EP3132801B1 (en) 2019-10-30
CA2936870C (en) 2019-11-26
HRP20170115T1 (hr) 2017-03-24
US20190010190A1 (en) 2019-01-10
WO2010037514A2 (en) 2010-04-08
CN102170901A (zh) 2011-08-31
JP5753783B2 (ja) 2015-07-22
EP3106175B1 (en) 2020-04-01
LT2331118T (lt) 2016-12-27
CA2936868C (en) 2019-10-22
US20160376315A1 (en) 2016-12-29
DK2331118T3 (da) 2017-01-09
CN102170900B (zh) 2016-10-26
JP6297632B2 (ja) 2018-03-20
RS60381B1 (sr) 2020-07-31
EA023013B1 (ru) 2016-04-29
LT3120869T (lt) 2020-11-10
CA2739387C (en) 2019-10-29
ES2607460T3 (es) 2017-03-31
US8961985B2 (en) 2015-02-24
UA103202C2 (ru) 2013-09-25
HUE049366T2 (hu) 2020-09-28
EP2172212B1 (en) 2016-10-05
BRPI0920791B1 (pt) 2022-01-18
CA2936982A1 (en) 2010-04-08
JP2016145210A (ja) 2016-08-12
ES2788129T8 (es) 2020-11-04
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
EP3069728B1 (en) 2018-11-14
KR20110074894A (ko) 2011-07-04
CY1121258T1 (el) 2020-05-29
ES2710608T3 (es) 2019-04-26
HUE049364T2 (hu) 2020-09-28
ES2804723T3 (es) 2021-02-09
LT3111952T (lt) 2018-12-27
US20150125478A1 (en) 2015-05-07
JP6294913B2 (ja) 2018-03-14
RS55531B1 (sr) 2017-05-31
LT3120868T (lt) 2020-08-10
EP2172211B1 (en) 2014-12-03
US8119139B2 (en) 2012-02-21
EP3106175A1 (en) 2016-12-21
DK3132801T3 (da) 2020-02-10
US20160376317A1 (en) 2016-12-29
EP2172212A3 (en) 2010-04-14
JP2017000148A (ja) 2017-01-05
HUE049367T2 (hu) 2020-09-28
US10227381B2 (en) 2019-03-12
PL3132801T3 (pl) 2020-06-15
CA2739387A1 (en) 2010-04-08
US10941181B2 (en) 2021-03-09
US8318677B2 (en) 2012-11-27
EA201401104A1 (ru) 2015-05-29
US20170326217A1 (en) 2017-11-16
EP2172212A2 (en) 2010-04-07
US11208434B2 (en) 2021-12-28
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
PT3132801T (pt) 2020-02-04
CY1121098T1 (el) 2019-12-11
US20210238227A1 (en) 2021-08-05
RS60385B1 (sr) 2020-07-31
ES2612466T3 (es) 2017-05-17
US20160355550A1 (en) 2016-12-08
CY1122913T1 (el) 2021-10-29
LT3069728T (lt) 2019-02-11
HUE050428T2 (hu) 2020-12-28
CA2936887C (en) 2019-11-12
CY1118702T1 (el) 2017-07-12
JP2017018102A (ja) 2017-01-26
JP5883476B2 (ja) 2016-03-15
EP2331118A1 (en) 2011-06-15
CA2936870A1 (en) 2010-04-08
US20210261614A1 (en) 2021-08-26
RS55043B1 (sr) 2016-12-30
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
PL3111952T3 (pl) 2019-04-30
MX2011003540A (es) 2011-06-20
EP3111952A1 (en) 2017-01-04
HRP20200988T1 (hr) 2020-10-16
JP6367266B2 (ja) 2018-08-01
HUE031030T2 (en) 2017-06-28
RS60386B1 (sr) 2020-07-31
SI3106175T1 (sl) 2020-08-31
SI3120869T1 (sl) 2020-10-30
PL2331118T3 (pl) 2017-05-31
HUE029360T2 (en) 2017-02-28
RS60338B1 (sr) 2020-07-31
NZ624533A (en) 2015-09-25
PT3106175T (pt) 2020-07-01
CA2936982C (en) 2019-12-03
CA2936887A1 (en) 2010-04-08
JP2017023136A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
DK2172211T3 (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS Inventors: Toni Weinschenk (Aichwald, DE) Oliver Schoor (Tubingen, DE) Oliver Schoor (Tubingen, DE) Claudia Trautwein (Wuelfrath, DE) Claudia Trautwein (Wuelfrath, DE) Norbert Hilf (Kirchentellinsfurt, DE) Norbert Hilf (Kirchentellinsfurt, DE) Steffan Walter (Reutlingen, DE) Harpreet Singh (Tuebingen, DE) Harpreet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
HK1161106B (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
HK1228271B (en) Novel immunotherapy against several tumors including neuronal and brain tumors
HK1224921A1 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
AU2016204712A1 (en) Novel immunotherapy against several tumors including neuronal and brain tumors